Ovarian Cancer Canada funds research into prevention, improved treatments, and ultimately a cure. Science continues to uncover new knowledge that impacts treatment and survival. Here’s how.
As recipient of a Teal Heart Scholarship,* Mauricio Medrano has dedicated a great deal of time to learning more about this disease. To date, his research focuses on high-grade serous ovarian cancer, which is the most common subtype. By identifying genes that enable tumours to survive, his work could help inform the development of more effective targeted treatments.
The push for an immediate additional investment of $10 million in federal funding to support ovarian cancer research continues. While government response to this appeal isn’t expected until early 2017, research efforts supported by Ovarian Cancer Canada continue to march forward thanks to Walk participants, generous donors, and strategic partners across the country.
An important resource for the research community, the tissue bank network collects and stores tissue samples from ovarian cancer patients. These samples and associated data are available to scientists and physicians studying ovarian cancer.
Women living with ovarian cancer and their families recently had the opportunity to hear directly from scientists as part of a session called “Ovarian Cancer Research and You.” This special presentation was held in conjunction with the 8th Canadian Conference on Ovarian Cancer Research, which convened leading minds in the field.
A champion for women living with ovarian cancer, Pat McDonald has done everything from co-chairing the Ovarian Cancer Canada Walk of Hope to serving on our Board of Directors to leading Knowledge is Power and Survivors Teaching Students® awareness sessions. A veritable force of nature, she has attended nearly every event in and around Halifax, gathering a faithful following over the years.
One of the world’s largest ever research trials recently posted findings that were 14 years in the making. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) estimates a new approach could reduce the number of lives lost to ovarian cancer by one-fifth (20 per cent).
Two promising studies were recently awarded joint funding by Ovarian Cancer Canada and the Cancer Research Society.
In the news recently, scientists at Lawson Health Research Institute have identified a new target for ovarian cancer therapies. New data shows that LKB1, a molecule previously thought to slow the growth of cancer, can also promote tumour survival.
In the news recently, research out of the Department of Biomedical Sciences at the University of Guelph shows potential to shrink ovarian tumours while improving drug delivery.
Ovarian Cancer Canada announces this year’s recipient of the Karen Campbell Award for Research Excellence. Congratulations to Dr. Barbara Vanderhyden.